Guifang Ouyang

15-Day Duration of Venetoclax Combined with Azacitidine in Treatment-Naive Higher-Risk Myelodysplastic Syndromes: A Prospective Multicenter Study

BinBin Lai, Chen Mei, Xiao Yan, Lieguang Chen et autres

BACKGROUND: Higher-risk myelodysplastic syndromes (HR-MDS) carry a high risk of progression to acute myeloid leukemia and poor overall survival. Hypomethylating agents (HMAs), such as azacitidine, remain the standard of care but have limited efficacy. A 15-day venetoclax-azacitidine regimen has shown promising objective …

cn (code pays fourni par la source)

Decitabine plus all-trans retinoic acid versus decitabine monotherapy for myelodysplastic syndromes with excess blasts: a multicenter, randomized controlled trial

Xinping Zhou, Yanjuan Lin, Yan Gao, Zheng Ge et autres

Despite standard treatment with hypomethylating agents, the prognosis of patients with higher-risk myelodysplastic syndrome (MDS) remains poor. All-trans retinoic acid (ATRA) has demonstrated promising efficacy in unfit patients with acute myeloid leukemia. This multicenter controlled trial randomized (1:1) untreated patients with MDS …

cn (code pays fourni par la source)

Mid-treatment CSF ctdna and MYD88 clearance outperform PET-CT in predicting response and survival to orelabrutinib-based induction in newly diagnosed PCNSL: A prospective biomarker study

Lixia Sheng, Yanli Lai, Sheng Nie, Yuning Pan et autres

Abstract Background Primary central nervous system lymphoma (PCNSL) is an aggressive extranodal non-Hodgkin lymphoma with limited tools for dynamic treatment response monitoring. ^18F-FDG PET-CT, while commonly used in systemic lymphomas, offers suboptimal predictive value in PCNSL due to CNS-specific limitations. Cerebrospinal fluid …

cn (code pays fourni par la source)

The Eastern Cooperative Oncology Group Score Rather Than Donor Type Impacts Clinical Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Severe Aplastic Anemia Patients Aged 51–60 Years: A Retrospective Study From the Chinese Blood and Marrow Transplant Registry

Xin Zhao, Ming Zhou, Bao‐Dong Ye, Erlie Jiang et autres

Our study includes 103 patients aged between 51 and 60 years who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) from matched sibling donors (MSDs) (n = 36), haploidentical donors (HIDs) (n = 56), and unrelated donors (URDs) (n = 11). Multivariate analysis …

cn (code pays fourni par la source)

Low serum complement C3 levels are associated with adverse clinical outcomes in myelodysplastic syndromes

Duobing Zou, Huanhuan Ying, Yong Liang, Jie Cao et autres

BACKGROUND: Complement C3, a critical component of the complement system, has been implicated in cancer risk across various malignancies. However, its role in myelodysplastic syndromes (MDS) remains inadequately explored. This study investigates the impact of serum complement C3 levels on survival outcomes …

cn (code pays fourni par la source)

LBA2 | ZANUBRUTINIB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS R‐miniCHOP IN UNFIT OR FRAIL PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA AGED 70 YEARS OR OLDER

Peng Xu, Zhenwei Shi, Fei Li, Guifang Ouyang et autres

cn (code pays fourni par la source)

756 | REAL‐WORLD STUDY OF GOLIDOCITINIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY PERIPHERAL T CELL LYMPHOMA: RETROSPECTIVE DATA FROM MEDICAL CENTERS IN CHINA

He Huang, Yan Gao, Guifang Ouyang, Li Liu et autres

Introduction: Diagnosing T-cell lymphoma (T-NHL) is often challenging due to phenotypic overlap with reactive T-cells.Antibodies targeting the two mutually exclusive isoforms of the constant TCR β-chain, TRBC1 and TRBC2, provide a unique opportunity to assess clonality, given that reactive T cells exhibit …

cn (code pays fourni par la source)

Rapid and simple detection of Candida albicans using closed dumbbell-mediated isothermal amplification

Yanli Zhang, Xuhan Chen, Fei Guo, Guifang Ouyang et autres

Introduction Candida albicans , a human fungal pathogen, multiplies to invade body cells and causes fungal diseases in the condition of insufficient body's immune function. Early detection of C. albicans is required to guide appropriate prevention and treatment. Methods The purpose of …

cn (code pays fourni par la source)

A Rare Case of Post-Transplant Lymphoproliferative Disorder Presenting as Hodgkin Lymphoma After Autologous Hematopoietic Stem Cell Transplantation: A Case Report and Literature Review

Yuzhan Chen, Ying Chen, Yimin He, Qitian Mu et autres

Abstract: Post-transplant lymphoproliferative disorder (PTLD) is a rare complication following hematopoietic stem cell transplantation (HSCT), with its occurrence post-autologous hematopoietic stem cell transplantation (auto-HSCT) being even rarer. Research on PTLD following auto-HSCT is exceedingly scarce. Here, we present a noteworthy instance wherein …

cn (code pays fourni par la source)

CAUSAL RELATIONSHIP BETWEEN HELICOBACTER PYLORI ANTIBODIES AND IMMUNE THROMBOCYTOPENIA: A MENDELIAN RANDOMIZATION STUDY

Yuzhan Chen, Qitian Mu, Guifang Ouyang

Background Previous observational studies have suggested a potential causal relationship between Helicobacter pylori (H. pylori) infection and Immune thrombocytopenia (ITP). However, the evidence for causal inference remains contentious, and the underlying mechanisms require further investigation. In order to delve deeper into the …

cn (code pays fourni par la source)

Decitabine Plus All-Trans Retinoic Acid Versus Decitabine Monotherapy for Myelodysplastic Syndromes with Excess Blasts: A Multicentre, Randomized Controlled Trial

Hongyan Tong, Xinping Zhou, Yanjuan Lin, Yan Gao et autres

Background: Hypomethylating agents (HMAs) are mainstay treatment of higher-risk myelodysplastic syndromes (MDS). However, clinical outcomes of patients treated with decitabine (DEC) monotherapy were far from satisfactory with an overall response rate (ORR) of 33%-55.4% and an overall survival (OS) of 17.7-22 months. …

cn (code pays fourni par la source)

Efficacy and Safety Results of TQB3909 in Patients (Pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Keshu Zhou, Hongyun Xing, Qingliang Teng, Wuping Li et autres

Background: TQB3909 is a novel, highly potent, orally bioavailable, and selective BCL-2 inhibitor that has shown safety profiles and preliminary antitumor activity under daily dose ramp-up scheme in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Aims: We …

cn (code pays fourni par la source)